Table 1 Patient characteristics and comparisons between acute cellular rejection (ACR) and no rejection (NR) groups
|  | ACR (n = 13) | NR (n = 33) | p-value |
|---|---|---|---|
No. patients (pediatric/adult)a | 4/9 | 8/25 | 0.72 |
Age at LT [median (range)] | |||
 Pediatric | 13 m (5–50 m) | 10.5 m (7–25 m) | 0.93 |
 Adult | 39 y (18–63 y) | 54 y (24–66 y) | 0.02 |
Sex (male/female) | 5/8 | 11/22 | 0.74 |
Living donor/brain death donor | 11/2 | 25/8 | 0.70 |
ABO incompatible | 3 (23.1%) | 4 (12.1%) | 0.39 |
Tacrolimus concentrations (mean ± SD) | 7.7 ± 1.5 | 8.0 ± 1.3 | 0.59 |
AST (mean ± SD) b | 197 ± 155 | 235 ± 406 | 0.75 |
ALT (mean ± SD) b | 409 ± 295 | 318 ± 366 | 0.43 |
Initially treated with mycophenolate mofetil | 9 (69.2%) | 20 (60.6%) | 0.74 |
Underlying disease | |||
 Biliary atresia | 4 (30.8%) | 6 (18.2%) | 0.44 |
 Primary sclerosing cholangitis | 2 (15.4%) | 6 (18.2%) | 1.00 |
 Primary biliary cholangitis | 2 (15.4%) | 3 (9.1%) | 0.61 |
 Fulminant hepatic failure | 1 (7.7%) | 4 (12.1%) | 1.00 |
 Hepatitis B | 2 (15.4%) | 2 (6.1%) | 0.57 |
 Hepatitis C | 1 (7.7%) | 3 (9.1%) | 1.00 |
 Autoimmune hepatitis | 1 (7.7%) | 2 (6.1%) | 1.00 |
 Others | 2 (15.4%) | 7 (21.2%) |  |
Days of hospitalization after LT [median (range)] | 86 (37–208) | 59 (24–326) | 0.25 |